Literature DB >> 21333643

CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists.

Brady K Atwood1, Donghoon Lee, Alex Straiker, Theodore S Widlanski, Ken Mackie.   

Abstract

'Spice' is an herbal blend that has been reported to produce cannabis-like effects when smoked and is marketed as an alternative to marijuana. Synthetic additives have been identified in numerous 'Spice' preparations from different sources. Common among many of the preparations were the compounds JWH018 and a dimethyloctyl variant of CP47,497 (CP47,497-C8) and, more recently JWH073. The synaptic effects of each of these compounds were uncharacterized. We previously reported that JWH018 is a potent and efficacious CB(1) cannabinoid receptor agonist. In this study we have examined the abilities of CP47,497-C8 and JWH073 to inhibit neurotransmission in cultured autaptic hippocampal neurons. Each inhibited EPSCs with an efficacy and potency similar to JWH018. We also analyzed these compounds' effects on promoting internalization of CB(1) receptors in HEK293 cells stably expressing CB(1) receptors. Similar to our neurotransmission data, CP47,497-C8 internalized CB(1) in a fashion indistinguishable from JWH018. However, JWH073 was less potent and produced slower internalization than JWH018 and CP47,497-C8. It appears that 'Spice' contains a number of cannabinoid receptor agonists that activate CB(1) receptors to inhibit synaptic transmission with similar potencies and efficacies. It is highly probable that the cannabis-like effects of 'Spice' are due to the presence of these and analogous synthetic additives acting on CB(1) receptors.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21333643      PMCID: PMC3094488          DOI: 10.1016/j.ejphar.2011.01.066

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  39 in total

1.  Molecular composition of the endocannabinoid system at glutamatergic synapses.

Authors:  István Katona; Gabriella M Urbán; Matthew Wallace; Catherine Ledent; Kwang-Mook Jung; Daniele Piomelli; Ken Mackie; Tamás F Freund
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

2.  Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling.

Authors:  Tanya L Daigle; Christopher S Kearn; Ken Mackie
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

Review 3.  Role of receptor internalization in opioid tolerance and dependence.

Authors:  Thomas Koch; Volker Höllt
Journal:  Pharmacol Ther       Date:  2007-11-17       Impact factor: 12.310

4.  Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.

Authors:  G Griffin; P J Atkinson; V M Showalter; B R Martin; M E Abood
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

5.  Chemical analysis of synthetic cannabinoids as designer drugs in herbal products.

Authors:  Nahoko Uchiyama; Ruri Kikura-Hanajiri; Jun Ogata; Yukihiro Goda
Journal:  Forensic Sci Int       Date:  2010-05-20       Impact factor: 2.395

Review 6.  The cannabinoid receptors.

Authors:  Allyn C Howlett
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

7.  Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors.

Authors:  Dai-Fei Wu; Li-Quan Yang; Andrea Goschke; Ralf Stumm; Lars-Ove Brandenburg; Ying-Jian Liang; Volker Höllt; Thomas Koch
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

8.  Receptor endocytosis counteracts the development of opioid tolerance.

Authors:  Thomas Koch; Antje Widera; Katharina Bartzsch; Stefan Schulz; Lars-Ove Brandenburg; Nicole Wundrack; Andrea Beyer; Gisela Grecksch; Volker Höllt
Journal:  Mol Pharmacol       Date:  2004-10-08       Impact factor: 4.436

9.  Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.

Authors:  D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

10.  Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.

Authors:  L S Melvin; G M Milne; M R Johnson; B Subramaniam; G H Wilken; A C Howlett
Journal:  Mol Pharmacol       Date:  1993-11       Impact factor: 4.436

View more
  45 in total

1.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

Review 2.  Poisoning and self-harm.

Authors:  D N Bateman
Journal:  Clin Med (Lond)       Date:  2012-06       Impact factor: 2.659

3.  Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats.

Authors:  Torbjörn U C Järbe; Hongfen Deng; Subramanian K Vadivel; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 4.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

Review 5.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 6.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

7.  Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.

Authors:  Brady K Atwood; James Wager-Miller; Christopher Haskins; Alex Straiker; Ken Mackie
Journal:  Mol Pharmacol       Date:  2011-11-07       Impact factor: 4.436

8.  Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.

Authors:  Kimberly L Samano; Justin L Poklis; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-05-09       Impact factor: 3.367

9.  Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.

Authors:  Kristen R Trexler; Sara R Nass; Molly S Crowe; Joshua D Gross; Margaret S Jones; Austin W McKitrick; David P Siderovski; Steven G Kinsey
Journal:  Drug Alcohol Depend       Date:  2018-07-07       Impact factor: 4.492

10.  Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Authors:  Maheswari Rajasekaran; Lisa K Brents; Lirit N Franks; Jeffery H Moran; Paul L Prather
Journal:  Toxicol Appl Pharmacol       Date:  2013-03-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.